Abstract
Neoadjuvant radiotherapy (RT) followed by total mesorectal excision is standard of care for locally advanced rectal cancer (LARC). Patient-reported outcome measures (PROM) are valuable for patient-centred information on side-effects and evidence-based recommendations – as patients might be willing to trade clinical advantages to maintain high quality of life (QoL). This study aims to report prospectively collected PROM after modern neoadjuvant radiotherapy for LARC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
